As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm behind its approved Duchenne muscular dystrophy (DMD) treatment.  | As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head,

A standoff over Elevidys could have major consequences for Duchenne patients, gene therapy companies and the perception of the FDA.

In light of recent patient deaths, the FDA has also revoked its platform designation for Sarepta’s AAVrh74 technology. The designation, granted last month, was the first of its kind to be announced publicly.